Clinical Trial Update: PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PSMA-targeted 18F-DCFPyL PET/MRI for detecting prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pylarify (piflufolastat F-18)

Snippet

Sponsor: Northwestern University | Conditions: Prostate Carcinoma | Phase 2 | Status: WITHDRAWN